Fabino Enterprises Share Price

India's economic growth to exceed 6.5% in FY26, says Moody's Ratings

Delhivery, Tata: Trading strategies in stocks that hit 52-week lows

Gensol Engineering shares plunge 50% in 12 days; rating downgrades weigh

Global funds' asset under custody see second-worst plunge amid market rout

Zydus Lifesciences to buy 86% stake in Amplitude Surgical for $280 million

Certificate under Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations 2018 for the quarter ended December 31 2022 dated January 11 2023 received from M/s Bigshare Services Private Limited the Registrar and Share Transfer Agent of the Company.

In continuation of our letter dated November 02 2022 pursuant to regulation 33 read with Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 the Unaudited Financial Results set out in compliance with Accounting Standards (AS) for the Half Year ended September 30 2022 duly approved by the Board of Directors of the Company in their meeting held on November 09 2022 together with Statement of Assets and Liabilities Cash Flow and Limited Review Report thereon are enclosed.

In continuation of our letter dated November 02 2022 pursuant to regulation 33 read with Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 the Unaudited Financial Results set out in compliance with Accounting Standards (AS) for the Half Year ended September 30 2022 duly approved by the Board of Directors of the Company in their meeting held today i.e. November 09 2022 together with Statement of Assets and Liabilities Cash Flow and Limited Review Report thereon are enclosed.

Fabino Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2022 inter alia to consider and approve In pursuant to Regulation 29(1) of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 this is to inform you that a meeting of the Board of Directors of Fabino Life Sciences Limited is scheduled to be held on Wednesday November 09 2022 at Registered Office of the Company at 105 Plot No 12 Barodia Tower 1st Floor D Block Central Market Prashant Vihar New Delhi-110085 inter-alia to discuss and approve among other items the Unaudited Financial Results and Statement of Assets and Liabilities for half year ended September 30 2022.Further in terms of the Code of Conduct of Company adopted under SEBI (Prohibition of Insider Trading) Regulations 2015 the trading window for dealing in the securities of the Company is already closed and shall open 48 hours after conclusion of the Board Meeting.

Certificate under Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations 2018 for the quarter ended September 30 2022 dated October 18 2022 received from M/s Bigshare Services Private Limited the Registrar and Share Transfer Agent of the Company.